drugset
drugset / Trial / NCT02032810

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

NCT02032810 ↗

Phase 1 Completed 17 enrolled H. Lee Moffitt Cancer Center and Research Institute Novartis · collab
NaSequentialOpen-labelTreatment

Summary

The purpose of this study is to find out if an investigational drug called panobinostat can be given safely with another drug called ipilimumab. Investigators want to learn more about the side effects of this combination of drugs using different doses of panobinostat and the same dose of ipilimumab.

Timeline

Start
2014-01-07
Primary completion
2017-09-06
Completion
2019-09-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipilimumab Monoclonal antibody 3 mg/kg —
Subject Panobinostat Small molecule 5 mg —
Subject Panobinostat Small molecule 10 mg —
Subject Panobinostat Small molecule 15 mg —
Subject Panobinostat Small molecule 20 mg —

Indications

melanoma skin cancer